NEW YORK (GenomeWeb News) – Bio-Reference Laboratories today said that it is making an equity investment of up to $6 million in molecular diagnostics firm InCellDx.

Under the terms of the agreement, Bio-Reference will purchase up to $6 million in shares of InCellDex's preferred stock and warrants representing between 20 percent and 25 percent of InCellDx, depending on dilution resulting from the exercise of outstanding options. The $6 million investment will be comprised of $4 million in cash and $2 million by promissory note.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

The House of Lords in the UK approves a bill to allow mitochondrial donation.